, /PRNewswire/ -- Coriolis Pharma, a globally operating service provider for R&D and GMP drug product development, R&D and GMP analytics and sterile drug product manufacturing support, announced the launch of a U.S. entity that allows customers to combine the convenience of a local service with the advantages of international expertise.
U.S. customers will be served by the U.
S.-based Coriolis commercial organization, which consists of business development and client project management professionals. Coriolis is also launching two novel platform services for developability assessment and pre-formulation screening, designed to de-risk and accelerate the path of antibody drug candidates to the clinic.
The new platform services are streamlined encapsulations of Coriolis' scientific experience with over 1,500 successful biologics development projects in all stages of development, including commercial products. The new U.S.
entity and platform services offer Coriolis clients more convenience and faster access to the company's scientific expertise, ensuring the long-term success of drug product development projects. "Because the U.S.
will remain the center of innovation for biopharmaceuticals and cell and gene therapies, we believe it is critical to provide in-market project management, business development, and logistical support to our U.S. clients," said Coriolis CEO .
"The establishment of our U.S. entity opens the next chapter in expanding the global footprint of Coriolis.
" Cor.
